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Background: Previous studies have reported differences in the use of cardiovascular medications for acute coronary syndromes according 
to the sex of the patient. A deliberate act to deny women proven treatment by their physicians seems unlikely. In order to contribute to a better 
understanding of the clinical decision making process in women, we analyzed which factors are associated with underutilization of evidence based 
therapies.
Methods: From the Canadian Registry of Acute Coronary Syndromes I and II, 6558 patients (4471 men and 2087 women) with a final diagnosis of 
acute coronary syndrome entered into the current analysis. Covariates were chosen using the approach described by Blackstone. The final selected 
model included 24 patient variables.
Results: Women were less likely than men to receive beta-blockers (75.76% versus 79.24%; p<0.01), lipid-modifying agents (56.37% versus 
65.44%; p<0.0001) and ACE inhibitors (55.52% versus 59.99%; p<0.01). Female sex and clinical decision not to investigate with cardiac 
catheterization were the strongest predictors (p<0.01) for not receiving lipid-modifying agents (OR 0.77, 95% CI 0.66 to 0.88; and OR 0.38, 95% CI 
0.15 to 0.57, respectively) and ACEI (OR, 0.74; 95% CI, 0.65.to 0.83; and OR 0.81, 95% CI, 0.76.to 0.94, respectively) at discharge. Age (OR 0.83, 
95% CI 0.78 to 0.88), Killip class 2 (OR 0.67, 95% CI 0.55 to 0.80) and Killip class 3/4 (OR 0.61, 95% CI 0.44 to 0.85) were significant (p<0.01) 
independent predictors of underutilization of beta-blocker use at discharge. Women were older (69±12 versus 64±12; p<0.01) with a higher 
prevalence of congestive heart failure (12.9% versus 8.9%; p<0.001), but they were less likely to be referred for cardiac catheterization (41.9% 
versus 49.6 %; p<0.001).
Conclusions: The findings demonstrate a serious underutilization of evidence-based treatments in women with acute coronary syndromes. 
Disparity largely depends on factors related to the patient (age), on factors related to the disease (congestive heart failure), and on factors related 
to the physician’s assessment of patient risk (decision to catheterize).
